Get started
Author

Javier Valencia

Observed names: J Valencia, J. Valencia, Valencia, Javier
Observed institutions: National Institutes of Health, Harvard University, Johns Hopkins University, Asociación Civil Impacta Salud y Educación, Johns Hopkins Medicine, University of California San Diego, University of Nebraska Medical Center
ORCID: 0000-0002-3635-1107
Observed ORCID: 0000-0002-3635-1107
OpenAlex ID: A5041288119
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
2019 · Susan Swindells, Ritesh Ramchandani, et al. · New England Journal of Medicine · 372
PDF
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
2019 · Beatriz Grinsztejn, Michael D Hughes, et al. · The Lancet HIV · 42
Antigenic competition in CD4 + T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
2019 · Esper G. Kallas, Nicole A. Grunenberg, et al. · Science Translational Medicine · 27
Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial
2020 · Markella V Zanni, Judith S Currier, et al. · The Journal of Infectious Diseases · 26
PDF
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
2023 · Mark A Marzinke, Brett Hanscom, et al. · The Lancet HIV · 21
PDF
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
2025 · Carl J Fichtenbaum, Carlos D Malvestutto, et al. · The Lancet HIV · 16
PDF
Prevalence of Intimate Partner Violence, Substance Use Disorders and Depression among Incarcerated Women in Lima, Perú
2021 · Elena Cyrus, Jorge Sanchez, et al. · International Journal of Environmental Research and Public Health · 15
PDF
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
2025 · Susan P Buchbinder, Sabrina Spinosa Guzman, et al. · The Lancet HIV · 14
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025 · Emma Davies Smith, Carlos Malvestutto, et al. · Open Forum Infectious Diseases · 13
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials
2021 · Simbarashe Takuva, Shelly T. Karuna, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 13
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
2020 · Carl J Fichtenbaum, Heather J Ribaudo, et al. · The Journal of Infectious Diseases · 13
PDF
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
2022 · Anchalee Avihingsanon, Michael D. Hughes, et al. · Journal of the International AIDS Society · 12
Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV
2023 · David M. MacDonald, Sarah Samorodnitsky, et al. · Scientific Reports · 3
PDF
Implementation of Daily Oral PrEP at HIV/AIDS Service Organizations in Lima, Peru: Early Findings From the PrEP PERU Demonstration Study
2026 · Pamela Ramírez, Alexander J. Lankowski, et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC) · 1
A latent trajectory analysis of young sexual and gender minorities’ adherence to three rectal microbicide placebo formulations (MTN-035; a randomized crossover trial)
2023 · Seul Ki Choi, José Bauermeister, et al. · BMC Public Health
PDF
Works count: 19
Citation count: 664
H-index: 13
I10-index: 15
Year
Topic
Type